How to manage bone disease in multiple myeloma By Dr. Andrew Yee Andrew Yee, MD of Massachusetts General Hospital Cancer Center shares his approach on how to manage bone disease in multiple myeloma and explains what the various treatment options are.
Read More
MarketReseachReports.biz has featured a report, titled “Contract Research Organization Market – Global Deals And Operational Strategies,” to its expanding repository of research reports. The report provides an in-depth analysis of reasons for the proliferation of contract research organizations as third-party service providers for biotechnology, pharmaceutical, and medical device companies. It finds out the deal-making behavior and […]
Read More
Niche market research is the key to your online business success. Here are nine online niche market research sites that will take you from brainstorming possible target market groups to in-depth niche keyword research. Just type the words in ‘italics’ into your search browser to get started. For brainstorming, generating content ideas, and clarifying what […]
Read More
Oncotarget: Induction of phenotypic changes in HER2-postive breast cancer cells IMAGE: RNAseq results demonstrating differences between normal, cancer, and redirected cells. view more Credit: Correspondence to – Brian W. Booth – brbooth@clemson.edu The cover for issue 30 of Oncotarget features Figure 4, “RNAseq results demonstrating differences between normal, cancer, and redirected cells,” by Frank-Kamenetskii, et al. […]
Read More
Look Past Covid Vaccine to Johnson & Johnson’s Drug Portfolio Look Past Covid Vaccine to Johnson & Johnson’s Drug Portfolio – GuruFocus.com Look Past Covid Vaccine to Johnson & Johnson’s Drug Portfolio – GuruFocus.com Bookmark of this page has been deleted. Pharmaceutical line will have a far greater impact on company’s earnings and stock price […]
Read More
NICE Recommends Isatuximab Plus Pomalidomide/Dexamethasone for Relapsed/Refractory … The United Kingdom’s National Institute for Health and Care Excellence (NICE) has recommended isatuximab-irfc (Sarclisa) in combination with pomalidomide and dexamethasone as a treatment option for select patients with relapsed/refractory multiple myeloma.1 The recommendation is specifically for patients who previously received lenalidomide (Revlimid) and a proteasome inhibitor, […]
Read More